Disease relevance of Monoclonal Gammopathies, Benign

• Monocyte chemotactic responsiveness was significantly depressed both in multiple myeloma patients (P less than 0.001) and in subjects with benign monoclonal gammapathy (P less than 0.001) as compared to that found in the control population [1].
• We studied 65 CSF and serum paired specimens from normals, multiple sclerosis (MS), other neurological diseases (OND) and benign monoclonal gammopathies (BMG) [2].
• Sera from 249 patients with monoclonal gammopathies (85 multiple myeloma, 92 benign monoclonal gammopathies, 53 cryoglobulinemia, 19 Waldenström's macroglobulinemia) were examined for the presence of anti-histone activity [3].

High impact information on Monoclonal Gammopathies, Benign

• Primary hyperparathyroidism and benign monoclonal gammopathy [4].
• In order to compare the patterns of somatic mutation in VH genes of mouse tumours with those of human counterparts, we have determined and analysed sequences of immunoglobulin VH genes in five cases of murine MM, two of WM and one of biclonal benign monoclonal gammopathy (BMG) [5].
• The role of genetic factors associated with the immunoglobulin heavy chain locus (Igh) in the development of benign monoclonal gammapathy (BMG), a benign B-cell proliferative disorder, was investigated in six Igh congenic mouse strains during ageing [6].
• Determination of the plasma cell growth fraction with the monoclonal antibody Ki-67 in monoclonal gammopathy may help to discriminate benign monoclonal gammopathy from multiple myeloma and will probably identify a subgroup of multiple myeloma patients with a poor prognosis, including those with relapsing multiple myeloma [7].
• The influence of genetic factors associated with the immunoglobulin heavy chain locus on the development of benign monoclonal gammapathy in ageing IgH-congenic mice [6].

Chemical compound and disease context of Monoclonal Gammopathies, Benign

• Generalized discoid lupus erythematosus with benign monoclonal gammopathy [8].
• Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy [9].

Gene context of Monoclonal Gammopathies, Benign

• Sera from 14 patients with an IgA M-component, six of whom had myelomatosis and eight with benign monoclonal gammopathy (BMG) were analysed [10].
• Almost a fifth of the patients with an apparently benign monoclonal gammopathy subsequently had a lymphoid malignant lesion (in one patient, more than 20 years after the detection of the serum M protein) [11].
• Occurrence of amyloid-related serum proteins in patients with benign monoclonal gammopathy [12].
• We found that the cases of benign monoclonal gammopathy (BMG) according to the conventional classification were in the MOMP-1 state, and myelomas could be classified into the MOMP-2 to MOMP-4 state [13].
• The SAA level was elevated in 16 to 32 patients with benign monoclonal gammopathy (BMG) [12].

Analytical, diagnostic and therapeutic context of Monoclonal Gammopathies, Benign

• In over 1200 cases examined by isoelectric focusing of CSF and serum proteins, 4 patients had benign monoclonal gammopathy [14].

References